Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy
Blood · 22.02.2024 · 143 (8) · 685-696
DOI: 10.1182/blood.2023021672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 22.02.2024. Verfasst von Johannes Duell und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Lymphoma. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS.
Abstract (Originalsprache)
CD19 chimeric antigen receptor (CAR) T cells and CD20 targeting T-cell–engaging bispecific antibodies (bispecs) have been approved in B-cell non-Hodgkin lymphoma lately, heralding a new clinical setting in which patients are treated with both approaches, sequentially. The aim of our study was to investigate the selective pressure of CD19- and CD20-directed therapy on the clonal architecture in lymphoma. Using a broad analytical pipeline on 28 longitudinally collected specimen from 7 patients, we identified truncating mutations in the gene encoding CD20 conferring antigen loss in 80% of patients relapsing from CD20 bispecs. Pronounced T-cell exhaustion was identified in cases with progressive disease and retained CD20 expression. We also confirmed CD19 loss after CAR T-cell therapy and reported the case of sequential CD19 and CD20 loss. We observed branching evolution with re-emergence of CD20+ subclones at later time points and spatial heterogeneity for CD20 expression in response to targeted therapy. Our results highlight immunotherapy as not only an evolutionary bottleneck selecting for antigen loss variants but also complex evolutionary pathways underlying disease progression from these novel therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany.
- Helmholtz Institute for RNA-based Infection Research, Helmholtz Center for Infection Research, Würzburg, Germany.
- Core Unit Bioinformatics, Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
- Institute of Pathology, University of Würzburg, Würzburg, Germany.
- Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Mildred Scheel Early Career Center, University Hospital of Würzburg, Würzburg, Germany.
ORCID-Profile: Alexander M Leipold, Silke Appenzeller, Hilka Rauert-Wunderlich, Oliver Dietrich, Christophe Toussaint, Fabian Imdahl, Florian Eisele, Antoine-Emmanuel Saliba, Leo Rasche
Förderung
- NHGRI NIH HHS
Zitieren
APA
Duell, J., Leipold, A. M., Appenzeller, S., Fuhr, V., Rauert-Wunderlich, H., Da Via, M., Dietrich, O., Toussaint, C., Imdahl, F., Eisele, F., Afrin, N., Grundheber, L., Einsele, H., Weinhold, N., Rosenwald, A., Topp, M. S., Saliba, A. E., & Rasche, L. (2024). Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy. Blood, 143(8), 685-696. https://doi.org/10.1182/blood.2023021672
Vancouver
Duell J, Leipold AM, Appenzeller S, Fuhr V, Rauert-Wunderlich H, Da Via M, et al. Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy. Blood. 2024;143(8):685-696. doi:10.1182/blood.2023021672
BibTeX
@article{Duell2024,
author = {Duell, Johannes and Leipold, Alexander M and Appenzeller, Silke and Fuhr, Viktoria and Rauert-Wunderlich, Hilka and Da Via, Matteo and Dietrich, Oliver and Toussaint, Christophe and Imdahl, Fabian and Eisele, Florian and Afrin, Nazia and Grundheber, Lars and Einsele, Hermann and Weinhold, Niels and Rosenwald, Andreas and Topp, Max S and Saliba, Antoine-Emmanuel and Rasche, Leo},
title = {Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy},
journal = {Blood},
year = {2024},
volume = {143},
number = {8},
pages = {685--696},
doi = {10.1182/blood.2023021672}
}
EUVIMED